Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026
Company Drug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Fineline Cube Jun 10, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...

Company Medical Device

Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System

Fineline Cube Jun 10, 2025

Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...

Company Drug

Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC

Fineline Cube Jun 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...

Company Drug

Innovent Biologics’ Xinbiyue Approved for Macau Market

Fineline Cube Jun 10, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...

Company Deals

Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug

Fineline Cube Jun 10, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...

Company Deals

Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market

Fineline Cube Jun 10, 2025

US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...

Company Drug

FDA Approves Merck’s Enflonsia for Infant RSV Protection

Fineline Cube Jun 10, 2025

The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...

Company Drug

Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial

Fineline Cube Jun 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Fineline Cube Jun 10, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Company Deals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Fineline Cube Jun 10, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...

Company

Huahai Pharma Receives FDA Warning Letter After Inspection

Fineline Cube Jun 10, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...

Company

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress

Fineline Cube Jun 9, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a...

Company Deals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

Fineline Cube Jun 9, 2025

China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...

Company Deals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

Fineline Cube Jun 9, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....

Company Drug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Fineline Cube Jun 9, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...

Company Drug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Fineline Cube Jun 9, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...

Company Deals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

Fineline Cube Jun 9, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21...

Company Deals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Fineline Cube Jun 9, 2025

Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...

Company Drug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

Fineline Cube Jun 9, 2025

China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...

Company Drug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101

Fineline Cube Jun 9, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...

Posts pagination

1 … 171 172 173 … 690

Recent updates

  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.